CompletedEUCTR 2013-001695-38
A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA
This historical record does not confirm current site availability.
Historical research recordAges 13–17Multiple countries
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Dothan and 89 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateAugust 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 327
- Sponsor
- SUNOVION PHARMACEUTICALS INC.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, United Kingdom, ...
- Age range
- From 13 Years to 17 Years
- Official registry ID
- EUCTR 2013-001695-38
- Official title
Show the full official title
A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA
Recruitment & locations
CompletedDothan, United States · Anaheim, United States · Bakersfield, United States
85 more locations
- Culver City, United States
- Downey, United States
- Garden Grove, United States
- Irvine, United States
- Orange, United States
- Panorama City, United States
- Riverside, United States
- Hartford, United States
- Washington D.C., United States
- Bradenton, United States
- Gainesville, United States
- Orlando, United States
- Sanford, United States
- Atlanta, United States
- Smyrna, United States
- Naperville, United States
- Lake Charles, United States
- Baltimore, United States
- Bloomfield Hills, United States
- Neptune City, United States
- New York, United States
- Rochester, United States
- Staten Island, United States
- Cincinnati, United States
- Cleveland, United States
- Oklahoma City, United States
- Memphis, United States
- Austin, United States
- Dallas, United States
- El Campo, United States
- The Woodlands, United States
- Orem, United States
- Charlottesville, United States
- Brussels, Belgium
- Rousse, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Varna, Bulgaria
- Barranquilla, Colombia
- Bello, Colombia
- Bogotá, Colombia
- Nantes, France
- Nice, France
- Budapest, Hungary
- Gyula, Hungary
- Lembah Pantai, Malaysia
- Culiacán, Mexico
- Monterrey, Mexico
- Daveo City, Philippines
- Iloilo City, Philippines
- Mandaluyong, Philippines
- Quezon City, Philippines
- Torun, Poland
- Tyniec Mały, Poland
- Warsaw, Poland
- Caguas, Puerto Rico
- Ponce, Puerto Rico
- San Juan, Puerto Rico
- Bucharest, Romania
- Iași, Romania
- Timișoara, Romania
- Lipetsk, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Tomsk, Russia
- Veliky Novgorod, Russia
- Yekaterinburg, Russia
- Incheon, South Korea
- Jeonju, South Korea
- Seoul, South Korea
- Torremolinos, Spain
- Barcelona, Spain
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kherson,Vil. Stepanivka, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Ternopil, Ukraine
- Vinnytsia, Ukraine
- Aberdeen, United Kingdom
- Birmingham, United Kingdom
- Edinburgh, United Kingdom
- Russia
Registry details
Original registry record (opens in a new tab)Historical country statuses
- Outside EU/EEA — Not reported
- Belgium — Completed
- Bulgaria — Completed
- Spain — Completed
- France — Ongoing
- United Kingdom — Completed
- Hungary — Completed
- Italy — Not Authorised
- Romania — Completed
Questions about this study
Who is behind this study?
The study sponsor is SUNOVION PHARMACEUTICALS INC.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia